Aerosolized Epigenetic Therapy for Metastatic Lung Cancer
雾化表观遗传疗法治疗转移性肺癌
基本信息
- 批准号:10760630
- 负责人:
- 金额:$ 86.11万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-19 至 2025-08-31
- 项目状态:未结题
- 来源:
- 关键词:Acute leukemiaAerosolsAirAir MovementsAzacitidineBrainBreathingCancer EtiologyCancer ModelCancer PatientCatabolismCellsCessation of lifeCharacteristicsChemicalsChronic Obstructive Pulmonary DiseaseClinicClinical ResearchCombination Drug TherapyCytidine DeaminaseCytosineDataDeoxycytidineDevicesDiagnosisDiseaseDocumentationDoseDrug KineticsDrynessDysmyelopoietic SyndromesEmulsionsEnzyme InhibitionEpigenetic ProcessEuropeEvaluationFDA approvedForced expiratory volume functionFormulationGene ExpressionGene SilencingGenesGeneticGenetic TranscriptionHalf-LifeHourHumanHypermethylationImmuneImmunotherapyInhalationInhalation ToxicologyInhalatorsInjectionsInvestigational DrugsLabelLegal patentLiverLungLung NeoplasmsMalignant NeoplasmsMalignant neoplasm of lungMethylationModelingNebulizerParticle SizePatientsPerformancePharmaceutical PreparationsPhasePhase I Clinical TrialsPowder dose formPractice GuidelinesProgression-Free SurvivalsPromoter RegionsRattusRegulatory PathwayRelapseReportingResearchResistanceRodentRodent ModelSafetySignal PathwaySmall Business Innovation Research GrantSolid NeoplasmStreamTechnologyTestingTherapeuticTissuesToxicologyTumor BurdenWorkabsorptionaerosolizedaqueouschemotherapyepigenetic therapyfirst-in-humangood laboratory practiceimmune activationimprovedin vivoinnovationmanufacturenovelnucleoside analogphase III trialpre-clinicalpressureprogramspromoterpulmonary functionquality assuranceresearch clinical testingresponsesafety studyscale upstandard of caresuccesstranscriptometranscriptome sequencingtumortumor heterogeneity
项目摘要
Project Summary
Lung cancer (LC) with over 2 million cases/year worldwide also remains the leading cause of cancer-
related death in the US and Europe. Treating LC remains challenging due to ~60% of patients presenting with
Stage IV disease, the heterogeneity of tumors with respect to genetic and epigenetic mechanisms that alter
gene expression, and treatment-related resistance. Combining chemotherapy with immunotherapy as the first
treatment option for advanced LC has significantly improved response rates and survival; however, median
duration for progression free survival (PFS) was still 8.8 versus 4.9 months for Stage IV LC patients receiving
chemo/immune versus chemotherapy with 69% and 49% alive at one year, respectively. Second line drugs
after relapse provide minimal benefit. Epigenetic deregulation involves cytosine methylation in the promoter
region of hundreds of genes to impede transcription leading to loss of expression. Thus, a therapy that could
reverse methylation and awaken these genes could produce durable and sustained tumor regression. The
cytosine nucleoside analogs 5-azacytidine (5AZA) and 5-aza-2’-deoxycytidine (DAC) inhibit the enzyme
responsible for cytosine methylation resulting in re-expression of genes silenced through cytosine promoter
hypermethylation. These FDA approved drugs are serving as potent therapy for blood-borne cancers,
myelodysplasia and acute leukemia. Epigenetic therapy for solid tumors including LC has been impacted by
the poor stability in an aqueous solution of 5AZA and DAC and catabolism by cytidine deaminase in liver and
GI. Lovelace Biomedical working with Bend Research/Lonza have overcome these barriers by developing a
stable dry powder (DP) formulation of 5AZA (5AZA-DP). The novel dry powder nebulizer (DryNeb) developed
by Nob Hill Therapeutics generates optimal aerosol particle sizes for local lung delivery-activity and optimal
systemic absorption characteristics while facilitating patients’ “easy” tidal breathing inhalation with no forced
pulmonary function maneuvers. In studies in which 5AZA-DP was delivered to tidally breathing rats, superior
pharmacokinetics were achieved in the liver, and most impressively to the brain with a half-life of 4 hours when
compared with injected aqueous solutions of 5AZA. Using a rat lung tumor model developed from instilling
cells obtained from human lung tumors, tidally inhaled 5AZA-DP reduced tumor burden by 70–95% for the 4
different non-small cell lung tumors evaluated, far exceeding the 32% reduction seen with systemic injection of
5AZA. A proof-of-concept clinical study showed stable localized lung cancer in 3 of 8 Phase I patients treated
with nebulized aqueous 5AZA. This Phase II SBIR through three specific aims builds on these exciting data by
focusing on performing formulation scale up and stability optimization of 5AZA-DP, aerosol performance in the
DryNeb, and GLP toxicology studies. Completion of these aims will support filing an investigational drug
application (IND) to the FDA to allow evaluation of 5AZA-DP using DryNeb in a Phase I dose escalation safety
study followed by a Phase IB study in LC patients who have relapsed on standard-of-care therapy.
项目概要
全球每年有超过 200 万例肺癌 (LC) 仍然是癌症的主要原因 -
美国和欧洲的相关死亡。治疗 LC 仍然具有挑战性,因为约 60% 的患者出现
IV 期疾病,肿瘤在遗传和表观遗传机制方面的异质性,改变
基因表达和治疗相关的耐药性。化疗联合免疫治疗为首
晚期 LC 的治疗选择显着提高了缓解率和生存率;然而,中位数
IV 期 LC 患者的无进展生存期 (PFS) 仍为 8.8 个月,而接受治疗的患者为 4.9 个月
化疗/免疫与化疗相比,一年存活率分别为 69% 和 49%。二线药物
复发后提供的益处微乎其微。表观遗传失调涉及启动子中的胞嘧啶甲基化
数百个基因的区域阻碍转录,导致表达丧失。因此,一种疗法可以
逆转甲基化并唤醒这些基因可以产生持久且持续的肿瘤消退。这
胞嘧啶核苷类似物 5-氮杂胞苷 (5AZA) 和 5-氮杂-2'-脱氧胞苷 (DAC) 抑制该酶
负责胞嘧啶甲基化,导致通过胞嘧啶启动子沉默的基因重新表达
超甲基化。这些 FDA 批准的药物可作为血源性癌症的有效治疗方法,
骨髓增生异常和急性白血病。包括 LC 在内的实体瘤的表观遗传学治疗受到以下因素的影响
5AZA 和 DAC 在水溶液中的稳定性较差,并且会被肝脏中的胞苷脱氨酶分解代谢,
地理标志。 Lovelace Biomedical 与 Bend Research/Lonza 合作,通过开发一种
5AZA (5AZA-DP) 的稳定干粉 (DP) 配方。开发出新型干粉雾化器(DryNeb)
Nob Hill Therapeutics 生产的气雾剂颗粒大小适合局部肺部输送活性和最佳
全身吸收特性,同时促进患者“轻松”潮式呼吸吸入,无需用力
肺功能演习。在将 5AZA-DP 给予潮式呼吸大鼠的研究中,
药代动力学是在肝脏中实现的,最令人印象深刻的是在大脑中,半衰期为 4 小时
与注射的 5AZA 水溶液相比。使用通过滴注开发的大鼠肺肿瘤模型
从人肺肿瘤中获得的细胞,潮式吸入 5AZA-DP 可使肿瘤负荷在 4 天内减少 70-95%
对不同的非小细胞肺肿瘤进行评估,远远超过全身注射 32% 的减少
5AZA。一项概念验证临床研究显示,8 名接受 I 期治疗的患者中有 3 名患有稳定的局限性肺癌
雾化 5AZA 水溶液。第二阶段 SBIR 通过三个具体目标建立在这些令人兴奋的数据的基础上:
专注于 5AZA-DP 的配方放大和稳定性优化,气雾剂性能
DryNeb 和 GLP 毒理学研究。完成这些目标将支持提交研究药物
向 FDA 提交申请 (IND),允许在 I 期剂量递增中使用 DryNeb 评估 5AZA-DP 的安全性
随后对接受标准护理治疗复发的 LC 患者进行 IB 期研究。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Steven A Belinsky其他文献
Early menopause and hormone therapy as determinants for lung health outcomes: a secondary analysis using the PLCO trial.
早期绝经和激素治疗作为肺部健康结果的决定因素:使用 PLCO 试验的二次分析。
- DOI:
- 发表时间:
2024 - 期刊:
- 影响因子:10
- 作者:
Xiaochun Gai;Yue Feng;Tessa M Flores;Huining Kang;Hui Yu;Kimberly K Leslie;Yiliang Zhu;Jennifer A Doherty;Yan Guo;Steven A Belinsky;Linda S Cook;Shuguang Leng - 通讯作者:
Shuguang Leng
Steven A Belinsky的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Steven A Belinsky', 18)}}的其他基金
Assessing Toxicant Properties and Health Effects of Cigarillo and Hookah Tobacco Aerosols in Rats
评估小雪茄和水烟气溶胶对大鼠的毒性特性和健康影响
- 批准号:
10413991 - 财政年份:2020
- 资助金额:
$ 86.11万 - 项目类别:
DNA Repair Capacity Assays for Lung Disease Risk Assessment
用于肺部疾病风险评估的 DNA 修复能力测定
- 批准号:
10470762 - 财政年份:2018
- 资助金额:
$ 86.11万 - 项目类别:
Assessing Toxicant Properties of Cigarillo and Hookah Aerosols in Lung Epithelial and Cardiac Cells Through Aerosol Exposure
通过气溶胶暴露评估小雪茄和水烟气溶胶对肺上皮和心肌细胞的毒性特性
- 批准号:
9788459 - 财政年份:2018
- 资助金额:
$ 86.11万 - 项目类别:
DNA Repair Capacity Assays for Lung Disease Risk Assessment
用于肺部疾病风险评估的 DNA 修复能力测定
- 批准号:
10296957 - 财政年份:2018
- 资助金额:
$ 86.11万 - 项目类别:
DNA Repair Capacity Assays for Lung Disease Risk Assessment
用于肺部疾病风险评估的 DNA 修复能力测定
- 批准号:
9768991 - 财政年份:2018
- 资助金额:
$ 86.11万 - 项目类别:
Assessing Toxicant Properties of Cigarillo and Hookah Aerosols in Lung Epithelial and Cardiac Cells Through Aerosol Exposure
通过气溶胶暴露评估小雪茄和水烟气溶胶对肺上皮和心肌细胞的毒性特性
- 批准号:
9976518 - 财政年份:2018
- 资助金额:
$ 86.11万 - 项目类别:
Deposition Profile and Toxicology of E-Cigarettes in the Oral Epithelium
电子烟在口腔上皮细胞中的沉积概况和毒理学
- 批准号:
9117092 - 财政年份:2016
- 资助金额:
$ 86.11万 - 项目类别:
Inhaled Delivery of Vidaza for Targeted Epigenetic Lung Cancer Therapy
吸入 Vidaza 用于靶向表观遗传肺癌治疗
- 批准号:
10208793 - 财政年份:2016
- 资助金额:
$ 86.11万 - 项目类别:
Inhaled Delivery of Vidaza for Targeted Epigenetic Lung Cancer Therapy
吸入 Vidaza 用于靶向表观遗传肺癌治疗
- 批准号:
10296534 - 财政年份:2016
- 资助金额:
$ 86.11万 - 项目类别:
Histone Methyltransferases as a Target for Lung Cancer Prevention
组蛋白甲基转移酶作为肺癌预防的靶点
- 批准号:
8856526 - 财政年份:2014
- 资助金额:
$ 86.11万 - 项目类别:
相似海外基金
AEROSOLS - AIR QUALITY AND HEALTH IMPACT OF PRIMARY SEMI-VOLATILE AND SECONDARY PARTICLES AND THEIR ABATEMENT
气溶胶 - 一次半挥发性颗粒和二次颗粒对空气质量和健康的影响及其消除
- 批准号:
10092043 - 财政年份:2024
- 资助金额:
$ 86.11万 - 项目类别:
EU-Funded
Development of a handheld rapid air sensing system to monitor and quantify SARS-CoV-2 in aerosols in real-time
开发手持式快速空气传感系统,实时监测和量化气溶胶中的 SARS-CoV-2
- 批准号:
10854070 - 财政年份:2023
- 资助金额:
$ 86.11万 - 项目类别:
Multispectral Sensor for Chemical Composition Analysis of Ultrafine Aerosols in Air Quality Assessment
用于空气质量评估中超细气溶胶化学成分分析的多光谱传感器
- 批准号:
10546675 - 财政年份:2022
- 资助金额:
$ 86.11万 - 项目类别:
Experimental Validation of CFD Modeling of Aerosols in Aircraft Cabins Considering Heating Ventilation and Air Conditioning (HVAC) Systems for COVID-19 & other Airborne Diseases
考虑适用于 COVID-19 的供暖通风和空调 (HVAC) 系统的机舱内气溶胶 CFD 建模的实验验证
- 批准号:
570756-2021 - 财政年份:2022
- 资助金额:
$ 86.11万 - 项目类别:
Alliance Grants
Multispectral Sensor for Chemical Composition Analysis of Ultrafine Aerosols in Air Quality Assessment
用于空气质量评估中超细气溶胶化学成分分析的多光谱传感器
- 批准号:
10887673 - 财政年份:2022
- 资助金额:
$ 86.11万 - 项目类别:
Using satellites to map the spatial characteristics of urban air pollution from aerosols at a time of climate change, health choices and pandemics
利用卫星绘制气候变化、健康选择和流行病时期城市气溶胶空气污染的空间特征
- 批准号:
2609674 - 财政年份:2021
- 资助金额:
$ 86.11万 - 项目类别:
Studentship
CINDAER Composition of indoor aerosols and their role in air quality
CINDAER 室内气溶胶的成分及其对空气质量的作用
- 批准号:
2599050 - 财政年份:2021
- 资助金额:
$ 86.11万 - 项目类别:
Studentship
Experimental Validation of CFD Modeling of Aerosols in Aircraft Cabins Considering Heating Ventilation and Air Conditioning (HVAC) Systems for COVID-19 & other Airborne Diseases
考虑适用于 COVID-19 的供暖通风和空调 (HVAC) 系统的机舱内气溶胶 CFD 建模的实验验证
- 批准号:
570756-2021 - 财政年份:2021
- 资助金额:
$ 86.11万 - 项目类别:
Alliance Grants
Development of a handheld rapid air sensing system to monitor and quantify SARS-CoV-2 in aerosols in real-time
开发手持式快速空气传感系统,实时监测和量化气溶胶中的 SARS-CoV-2
- 批准号:
10273983 - 财政年份:2021
- 资助金额:
$ 86.11万 - 项目类别:
Biomass Burning Flux Measurements of Trace Gases and Aerosols (BB-FLUX) Using Solar Occultation Flux (SOF) on the Wyoming King Air
使用怀俄明 King Air 上的太阳掩星通量 (SOF) 测量微量气体和气溶胶 (BB-FLUX) 的生物质燃烧通量
- 批准号:
1754019 - 财政年份:2018
- 资助金额:
$ 86.11万 - 项目类别:
Continuing Grant